Abstracts must be submitted only in English consisting of five paragraphs with the following headings:
Background / Introduction
Objective/Aim
Methods
Results
Conclusion
References/Further sources of information
- Abstracts can be amended in the online submission system prior to the extended and final submission deadline of 25 May 2022. After the submission deadline, all abstracts will be automatically considered to be fully submitted and will proceed to the peer review.
- Up to 15 authors can be submitted for an abstract (including the presenting author). The presenting author is selected first; other authors can be added only when the presenting author is submitted. However, the author order can be changed if needed by swapping the names in the list of the authors. The first name is always considered to be the main author.
- All accepted abstracts will be published in Drug Safety, ISoP official journal. We recommend having your abstract checked for correct spelling, punctuation, grammar, and formal structure before submitting.
- Please check that references are cited in the text. There is a possibility that references will be deleted during production if they are not cited in text.
- The organiser reserves the right to edit abstracts, if necessary, prior to the publication in Drug Safety.
- The intent of this year’s Meeting is to provide high-quality sessions focused on educational content that is free from commercial influence or bias. We request all presenters to co-operate with this by declaring during the abstract submission process that the abstract is unpublished and original material.
Disclaimer
ISoP requests that a high standard of science is followed concerning publications and presentations at all its Annual Meetings and training courses. However, ISoP as a whole or its Executive Committee (EC) or appointed Scientific Committees, or its members, do not take any responsibility for the completeness or correctness of data or references given by authors in publications and presentations at official scientific meetings. It is not within the remit of ISoP, the EC or Scientific Committees in particular, to seek clarification or detailed information from authors about data in submitted abstracts. Moreover, it is not within the scope of ISoP and its committees to monitor compliance with any legal obligations, e.g. reporting requirements or regulatory actions.
Abstract Layout
Figures: these cannot be included.
Click the “Upload” button and select the picture you wish to insert from your computer. It will be uploaded to the insert image gallery.
Select the corresponding picture, copy the picture title into the “Alternate Text” field and add the picture dimensions (one size is enough) and confirm the selection with the ”Insert” button. (width 300px = approx. 7cm wide)
When the picture is uploaded, the correct location and size can be checked. If you wish to change the dimensions you can simply delete the inserted picture and upload it once again with a different size.
IMPORTANT! The title of your table (in jpg) has to be written in the abstract text above the picture, not only in the “Alternate Text”.
Please check carefully if your picture was uploaded successfully. You would see it in the abstract overview at the end of the submission.
For an example of a correctly formatted abstract please see below.
Abstract Example
Risk Factors for Developing Serious Adverse Drug Reactions
Introduction: Serious adverse drug reactions (ADRs) constitute major concerns in terms of both individual outcomes (e.g. deaths and hospitalizations) and public health expense. Several studies have been conducted to assess the importance and economic consequences of ADRs.[1-4] However, such work has not been previously undertaken in Croatia.
Aim: To identify risk factors associated with developing a serious ADR.
Methods: We performed a retrospective observational study of the ADRs reported to the Croatian Agency for Medicinal Products and Medical Devices for the period from March 2005 to December 2006. All drugs were classified using the Anatomical Therapeutic Chemical (ATC) classification code system, and subsequently entered into a database. ADRs were considered serious if one of the following criteria were met according to the ICH E2A guidelines: the ADR is life threatening; it led to hospitalization/prolonged stay in hospital; caused congenital malformation; permanent disability; or, medically serious condition. Descriptive statistics and logistic regression using SPSS 14.0 were undertaken.
Results: The results showed that among all the reported ADRs (n = 898), 26.1% referred to serious ADRs (n = 234). The majority of these serious ADRs (59.4%) were caused by drugs belonging to N (25.7%), J (18.5%) and, C (15.2%) ATC groups. From this database of ADRs, polypharmacy was associated with an increased risk of experiencing a serious ADR (B = 1.226; R2 = 0.026; p < 0.005). The relationship between serious ADRs, patient demographics and drug interactions were explored as well.
Conclusions: This study has identified factors that contributed to developing serious ADRs reported to Croatian Agency for Medicinal Products and Medical Devices. These data will be used for development of national risk management plans.
References
- Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998; 279: 1200-5
- Einarson TR. Drug-related hospital admissions. Ann Pharmacother 1993; 27: 832-40
- Bates DW, Spell N, Cullen DJ, Burdick E, Laird N, Petersen LA, et al. The costs of adverse drug events in hospitalized patients. JAMA 1997; 277: 307-11
- Moore N, Lecointre D, Noblet C, Mabille M. Frequency and cost of serious adverse drug reactions in a department of general medicine. Br J Clin Pharmacol 1998; 45: 301-8